Johnson & Johnson: Lymphoma trials

The registry lists 33 Lymphoma studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 11 have results posted.

Phase 1 9Phase 2 8Phase 3 6Phase 4 2No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCompletedNCT03384654Phase 2Results posted
• A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p DeletionCompletedNCT03190330Phase 4Results posted
• A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal TypeCompletedNCT02927925Phase 2Results posted
• A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin LymphomaTerminatedNCT02703272Phase 3Results posted
• An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular LymphomaTerminatedNCT02413489Phase 2Results posted
• A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin LymphomaCompletedNCT01974440Phase 3Results posted
• A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/LymphomaCompletedNCT01973387Phase 3Results posted
• A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell LymphomaCompletedNCT01855750Phase 3Results posted
• A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)CompletedNCT01804166Phase 4Results posted
• Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior TherapyCompletedNCT01646021Phase 3Results posted
• A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01611090Phase 3Results posted
• A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)CompletedNCT03900598Phase 1
• Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From IndiaCompletedNCT03476655
• A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical PracticeCompletedNCT03425591
• Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese ParticipantsCompletedNCT03053024
• An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative ColitisActive, not recruitingNCT02808780
• Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in LymphomaWithdrawnNCT02743546Phase 1
• Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin AmericaCompletedNCT02559583
• A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell MalignanciesTerminatedNCT02454270Phase 1
• Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT02169180Phase 2
• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or LymphomaCompletedNCT01962532Phase 1
• An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular LymphomaTerminatedNCT01902862Phase 2
• An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell LymphomaApproved for marketingNCT01833039
• A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular LymphomaCompletedNCT01779791Phase 2
• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or LymphomaCompletedNCT01703481Phase 1
• A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib TherapyCompletedNCT01599949Phase 2
• A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01572519Phase 1
• A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin LymphomaCompletedNCT01569750Phase 1
• A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell LymphomaCompletedNCT01486277Phase 2
• Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of NetherlandsCompletedNCT00731536
• A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma.CompletedNCT00677105Phase 1
• An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn's Disease.CompletedNCT00440817
• A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's DiseaseCompletedNCT00412321Phase 1